30033-24-0

Basic information

• Product Name: N-(tert-buloxycarbonyl)-3,4-dihydroxy-L-phenylalanine
• Synonyms: N-(tert-buloxycarbonyl)-3,4-dihydroxy-L-phenylalanine;N-(tert-Buloxycarbonyl)-3-hydroxy-L-tyrosine;N-(tert-Butyloxycarbonyl)-L-dopa;N-(tert-Butoxycarbonyl)-3,4-dihydroxy-L-phenylalanine;N-[(1,1-dimethylethoxy)carbonyl]-3-hydroxy- L-Tyrosine;2-tert-Butoxycarbonylamino-3-(3,4-dihydroxy-phenyl)-propionic acid
• CAS NO: 30033-24-0
• Molecular Formula: C₁₄H₁₉NO₆
• Molecular Weight: 297.3
• Mol File: 30033-24-0.mol
• Article Data: 31

Chemical Properties

• Boiling Point: 532.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.318
• PKA: 2.98±0.10(Predicted)
• CAS DataBase Reference: N-(tert-buloxycarbonyl)-3,4-dihydroxy-L-phenylalanine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(tert-buloxycarbonyl)-3,4-dihydroxy-L-phenylalanine(30033-24-0)
• EPA Substance Registry System: N-(tert-buloxycarbonyl)-3,4-dihydroxy-L-phenylalanine(30033-24-0)

Safety Data

• Hazardous Substances Data: 30033-24-0(Hazardous Substances Data)

Usage

General Description

N-(tert-butoxycarbonyl)-3,4-dihydroxy-L-phenylalanine, also known as Boc-DOPA, is a chemical compound primarily used in the synthesis and modification of various bioactive compounds and pharmaceuticals. Boc-DOPA is a derivative of the amino acid L-phenylalanine and is commonly used as a protecting group in peptide synthesis to prevent unwanted reactions at specific sites. It is also used in the preparation of dopamine and other biologically active compounds. Boc-DOPA has been studied for its potential applications in the treatment of neurological disorders, such as Parkinson's disease, and as a precursor for the synthesis of other important molecules. Overall, Boc-DOPA plays a crucial role in organic synthesis and pharmaceutical research due to its unique chemical properties and versatile applications.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 59-92-7 levodopa 
• 24424-99-5 di-tert-butyl dicarbonate 
• 161392-58-1 3,4-bis(tert-butyldimethylsilyloxy)-L-phenylalanine 
• 364619-17-0 3,4-bis(tert-butyldimethylsilyloxy)-N-(9-fluorenylmethyloxycarbonyl)-L-phenylalanine 

Downstream Products

• 783333-86-8 (2S)-2-tert-butoxycarbonylamino-3-[4-(prop-2-ynyloxy)phenyl]-propionic acid propargyl ester 
• 158955-67-0 (2S)-3-[3,4-bis[(tert-butyldimethylsilyl)oxy]phenyl]-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 940879-09-4 (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-(tert-butoxycarbonyl)amino-3-(3,4-dihydroxyphenyl)propanoate 
• 940879-06-1 (2R)-2-(phenylcarbonyloxy)propyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate 
• 1395347-24-6 (trans-5,9a)-5-(5-chloro-1H-indol-3-yl)-8-methyl-7,8,9a,10-tetrahydro-5H-1,3-dioxa-5a,8-diaza-cyclopenta[b]anthracene-6,9-dione 
• 138908-56-2 (S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester 

Relevant articles and documents

BORON CLUSTER-COUPLED COMPOUND

To provide a novel boron-containing compound which increases intratumorous accumulation and tumor retention, and is efficiently taken into a tumor cell.SOLUTION: The present invention relates to a compound represented by formula (I) in the figure or a salt thereof. [In the formula, X represents a divalent to pentavalent organic group; Y represents a linker structure; R represents a monovalent group comprising boron clusters; and n represents 2, 3, 4 or 5.SELECTED DRAWING: None

PROTAC targeting the degradation of tyrosinase and its applications

The present invention relates to PROTAC targeting tyrosinase and its applications, belonging to the technical field of new raw materials for skin whitening cosmetics and skin disease treatment drugs. The technical problem solved by the present invention is to provide a compound using PROTAC targeting the degradation of tyrosinase and its salts, prodrugs, hydrates or solvates. The PROTAC molecule, whose structural formula is shown in formula I. The present invention by different types, different chain lengths of the linker will be tyrosinase ligand and E3 ligase ligand coupling, successfully prepared a series of targeted tyrosinase PROTAC molecules, can effectively target the target protein, and reduce the content of tyrosinase in the cell, while having a good in vitro reducing melanin effect, low toxicity to normal cells, in line with the characteristics of high efficiency and low toxicity.

Delivery of a system xc?inhibitor by a redox-responsive levodopa prodrug nanoassembly for combination ferrotherapy

A comprehensive understanding of ferroptosis signaling pathways significantly contributes to the advances in cancer ferrotherapy. Herein, we constructed a self-assembled prodrug nanosystem targeting system xc?, a key regulator for ferroptosis, to amplify the therapeutic efficacy of cancer ferrotherapy. The prodrug nanosystem is assembled between sulfasalazine (SSZ, a ferroptosis resistance inhibitor) and disulfide-bridged levodopa (DSSD) that can chelate Fe2+ions to form SSZ-Fe2+@DSSD, and the resulting nanoassembly can not only inhibit ferroptosis resistance, but also generate ROS in the tumor microenvironment. Whereas the prodrug nanosystem is stable in the physiological environment, it becomes unstable in the tumoral and intracellular reductive microenvironment, where the disulfide linkers are disrupted by high levels of glutathione (GSH), triggering the release of active Fe2+and SSZ. Under the Fenton reaction, the released Fe2+thus can induce ferroptosis, which is amplified by SSZ-mediated inhibition of ferroptosis resistance to synergistically improve the therapeutic efficacy of ferroptosis. Our study thus provides an innovative prodrug strategy to advance anticancer ferroptosis.